Chemokine CXCL13, also known as BCA-1 (B-cell attracting chemokine-1) or BLC (B-lymphocyte chemoattractant), is a major regulator of B cell trafficking.
INTRODUCTION
Chronic active liver disease (CALD) is an inflammatory disorder recognizing several etiologies and different pathogenetic mechanisms (1) . Within inflamed liver, there is an accumulation of lymphoid and myeloid cells, including T and B cells (2) .
Local activation of these cells is thought to be essential in perpetuating the chronic inflammatory process and accelerating liver damage (3) . T and B cells in CALD frequently accumulate in the portal tracts and organize follicle-like structures, with features of germinal centers (GC) (4) . In these sites, local differentiation of follicular dendritic cells, plasma cells and antibody production may occur (5) .
In hepatitis C virus (HCV) infection, distinct B cell expansions contribute to the formation of intraportal follicle-like structures (6, 7) . Circulating B-cell clonotypes have been suggested to be of hepatic origin, indicating that IgH VDJ mutational activity is up-regulated in the hepatic microenvironment (8) . Sequence analyses of IgH CDR-3 gene segments of intraportal B cell clonalities have revealed a wide range of variations, possibly implying that they are the result of an antigen-driven response (9) . The occurrence of B cell clonal expansions in the liver of HCV-infected patients has been found to deeply influence the clinical picture, which appears to be strictly related to mixed cryoglobulinemia (MC) and, in general, to lymphoproliferative stigmata including high serum levels of rheumatoid factor (RF) and monoclonal gammopathy of undetermined significance (8) . The relationship between emergence and persistence of intrahepatic or circulating B-cell clonotypes and HCV infection is still unknown. Accumulating evidence indicates that certain chemokines play a critical role in providing the appropriate environment for activation and expansion of naïve lymphocytes in response to signals delivered by antigen-presenting cells (10) . CXC ligand13 (CXCL13), also known as B cell-attracting chemokine 1 or Blymphocyte-chemoattractant, is a member of CXC subtype of chemokine superfamily (11) . It is critical for secondary lymphoid tissue development and distribution of lymphocytes within microenvironments (12) . The gene mapped to chromosome segment 4q21 encodes a putative protein of 109 amino acids (11, 12) . The primary CXCL13 receptor is CXCR5, a 7-transmembrane G-protein expressed by B lymphocytes (13) , follicular B helper T cells (14) , osteoblasts (15) , podocytes (16) , and skin-derived dendritic cells (17) . Interestingly, CXCL13 and CXCR5 knockout mice exhibit similar abnormalities, including impaired development of peripheral lymphoid organs, reduced B cell translocation to the B/T cell boundary and a lower antibody response (18) . CXCL13 is constitutively expressed in the B cell follicles of secondary lymphoid organs (11) , pleural and peritoneal cavities (18) , and in ectopic lymphoid follicles within the synovial membrane of patients with rheumatoid arthritis (19) .
We sought to determine the plasma levels of CXCL13 in patients with chronic HCV infection, with or without MC, a chronic B-cell lymphoproliferative disorder characterized by systemic vasculitis, which can potentially progress to frank B-cell non-Hodgkin's lymphoma (20) . Our data indicate that the high serum levels of CXCL13 protein in MC patients parallel those of specific mRNA expression in the liver and in the skin, and suggest that this chemokine plays a major role in the pathogenesis of cryoglobulin-related damage, likely through B cell deregulation and local production.
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For personal use only. on August 31, 2017 . by guest www.bloodjournal.org From Activity score and degree of fibrosis in liver biopsy were evaluated according to Ishak et al (21) . Among the 46 selected patients, serum cryoglobulins, isolated as described elsewhere (22) , were detected in 20 (16 of type II and 4 of type III) in whom skin biopsy was provided under local anesthesia. Control skin samples were derived from: a) 4 healthy patients undergoing cosmetic surgery; b) 5 HCV-infected patients without MC who were subjected to saphenectomy; c) 3 patients with HCVnegative hypersensitivity vasculitis; d) 2 HBV-positive patients with necrotizing vasculitis; e) 5 patients with Henoch-Schönlein purpura; f) 2 with HCV and HBVnegative cryoglobulinemia. As controls, 5 liver samples from patients with nonalcoholic steatosis and 5 with near-normal liver obtained during cholecystectomy were considered.
MATERIAL AND METHODS

Patients and controls
During
Liver and skin biopsy specimens were in part formalin-fixed and paraffinembedded for routine histological examination, and in part embedded in optimal cutting temperature (OCT; Miles Scientific, Naperville, IL, USA), snap-frozen and stored at -80°C until sectioning for use in immunofluorescence studies. Part of the biopsy samples was prepared for molecular analyses; the specimens were put in a
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Results of liver histology, epidemiology, virology and laboratory parameters are reported in Table 1. HCV-infected patients, with or without MC, were treated with pegylated interferons (PEG-IFNs) and ribavirin (RBV) (23) . Those infected with genotypes 2 or 3 were treated for 6 months, whereas all other patients received 12 months of antiviral therapy. Patients were reassessed 6 months after discontinuation of therapy to determine whether they had achieved a sustained virological response (SVR) (serum HCV RNA undetectable 6 months after treatment cessation). In the MC group, therapeutic response was evaluated as previously established (24) . Complete response was defined as reduction of the cryocrit level to less than 25% of the initial value, associated to the disappearance of at least two of the following signs and symptoms: purpura, arthralgias and weakness.
Patients unresponsive to PEG-IFN/RBV combination therapy underwent B-cell depletion with an anti-CD20 monoclonal antibody (Rituximab) (Hoffmann-La Roche AG, Grenzach-Wyhlen, Germany). They received 4 intravenous infusions of 375 mg/m 2 once a week over a period of a month (25) . After Rituximab treatment, patients were evaluated monthly for a period of 6 months. Those who were shown to be refractory also to anti-CD20 antibody therapy were given corticosteroids (6-methylprednisolone, 16 mg/die).
RT-PCR for CXCL13 mRNA expression
RNA was extracted from skin biopsy samples using TRIzol (Invitrogen Life Technologies, Gaithersburg, MD, USA) and reverse transcribed with oligo(dT) (Invitrogen Life Technologies) and random hexamer primers (Invitrogen Life Technologies). PCR was carried out with Taq DNA polymerase (AmpliTaq Gold, Applied Biosystem, Foster City, CA, USA). Primer pair for CXCL13 was: CAG AAT CCT CTG GAA CTT GAG (5') and CTT CCA GAC ATT CGG AGA CC (3') (19) . As control, transcripts of the "housekeeping" gene β-actin were amplified (GTC CTC TCC CAA GTC CAC ACA (5') and CTG GTC TCA AGT CAG TGT ACA GGT AA (3').
Annealing temperatures were 58°C for CXCL13 and 56°C for β-actin. PCR products resolved on 3% agarose gel were 368bp the CXCL13 cDNA size and 241bp that of 
Immunofluorescence for CXCL13 protein
Indirect immunofluorescence to detect CXCL13 in liver and skin biopsy samples was performed with goat anti-human CXCL13 antibody (R&D Systems, Inc)
at working concentration of 15 µg/ml. Tissues were cut into 6 µm sections, dried at r.t. for 1 hr, and fixed in acetone at -20°C. Human tonsil sections were treated in the same manner as positive control. Samples were incubated with primary antibody for 3 hr at r.t. Isotype-matched antibodies were used for control staining. Thereafter, FITC-conjugated rabbit anti-goat antibody, F(ab)' 2 fragment (Dako, Glostrup, Denmark), was used as the secondary reagent. It was incubated for 2 hr at r.t..
Slides were then cover-slipped with aqueous medium and evaluated under fluorescence microscopy. To block positive reaction on selected samples, the primary antibody was pre-incubated with human recombinant CXCL13 protein (5 ng/ml) (R&D Systems Inc.). Omission of primary antibody and use of irrelevant antibody (anti-human chorionic gonadotropin: HCG) were also performed.
Statistical analysis
Significance of differences in the distribution of quantitative variables was assessed with one-way analysis of variance. All p values were 2-tailed and a level of 0.05 was considered statistically significant. The probability of response to therapy was assessed by the Kaplan-Meier method. Cox's regression model was used for univariate analysis to measure degree of association between serum levels of CXCL13 and virologic and immunologic parameters.
RESULTS
Study population
Twenty patients with MC (16 of Type II and 4 of Type III) and 26 without extrahepatic disorders were considered in this study. As reported in Table 1 , all were chronically infected with HCV. The number of females was significantly higher in MC patients (p<0.05). CALD was histologically defined in the patients of the two groups, in which cirrhosis was almost equally distributed. Except for a moderate prevalence of HCV genotype 2 in MC patients, no distinct profile of their distribution was detected.
Skin histology from the MC group showed leukocytoclastic vasculitis in 5 patients, and lymphocytic vasculitis in 4, whose clinical presentation was characterized by palpable purpura at lower extremities, leg ulcers, and blistering erythematous urticarial plaques. Pandermal vasculitis included thrombosis and severe endothelial cell alterations. Eleven patients belonging to the asymptomatic group showed pauci-inflammatory vasculopathy, focal perivascular infiltrates and sparse, hyalinizing vascular changes.
Serum CXCL13 protein
Compared with 30 healthy blood donors (19 men and 11 females with a mean age of 55±11 yr), serum CXCL13 levels showed progressively higher mean levels when patients without and with MC were considered (48.2 ± 11.0 vs 113.9 ± 40.2 pg/ml, mean ± SD: p<0.01; vs. 273.6±98 pg/ml, mean ± SD: p<0.005, respectively).
Cross-sectional analysis showed that CXCL13 serum levels in MC patients were significantly higher than those found in patients without MC (p<0.04).
The relationships between CXCL13 serum levels and virological, histological, and immunological parameters are depicted in Table 2 . In each group, no correlation was observed between CXCL13 concentration and circulating viral load, liver histology activity index or grade of liver fibrosis and ALT levels. In addition, in MC patients no correlation was seen between CXCL13 levels and cryocrit percentages, serum IgM, RF activity, and C4 concentration.
Patients of the MC group were stratified according to the occurrence of active or non-active phase of cutaneous vasculitis. Laboratory findings and clinical features of the 2 subgroups are summarized in Table 3 . Though not significant, the average cryocrit value was lower in patients with active vasculitis, whereas type III MC occurred more frequently in those with non-active vasculitis. Serum γ-globulin and IgM levels, RF activity and complement C4 concentration were almost similar in the 2 subgroups, and not dissimilar was the frequency of nephropathy and peripheral neuropathy. Conversely, a significantly higher value (p<0.001) of CXCL13 serum concentration was demonstrated in patients with active cryoglobulinemic vasculitis, whereas the mean serum concentration of CXCL13 in MC patients without active vasculitis was comparable to that found in non-MC patients.
In situ CXCL13 immunodetection and gene quantitation CXCL13 protein, studied by indirect immunofluorescence on skin biopsy samples of cryoglobulinemic patients, was mostly expressed along interstitial array between collagen bundles and involved the superficial dermis with variable mild/deep dermal extension in patients with active vasculitis (Fig. 1B) . No CXCL13-protein deposition was detected in skin biopsy tissues from controls that included healthy subjects and HCV-infected patients without MC (Fig. 1C) . Hepatocytes and bile duct epithelium were not stained. On the contrary, intense expression of CXCL13 protein was evident in inflammatory cells within portal tracts and, less frequently, into the sinusoids. The following two main immunofluorescence patterns of CXCL13 protein expression were established: i) granular bead-like deposits mimicking follicle-like structures within portal tracts (Fig. 2B) ; ii) fine as well as coarse dot-like immunofluorescence diffusely extending to the entire region of portal tract or confined to some defined areas (Fig. 2C) . Furthermore, CXCL13-containing cells were found into sinusoidal inflammatory cells ( Fig. 2C and 3C ).
Indeed, CXCL13 follicle-like labeling pattern and intrasinusoidal positivity were features more frequently found in patients with MC (83%) than in those without (31%). Sometimes, the 2 features of CXCL13 immunodetection coexisted in the same section.
Assessment of CXCL13 specificity was carried out on both liver and skin positive samples before and after the absorption of the probe with recombinant CXCL13 protein. Pre-incubation with CXCL13 protein completely abolished the positive signal, whereas the signal was unchanged when an irrelevant protein (HCG:
human chorionic gonadotropin) was used (data not shown).
Quantitative real-time RT-PCR assay for specific CXCL13 mRNA expression was performed on nucleic acids recovered from LCM-based microsamples. Several laser pulses were used to obtain microdissected portal tracts of comparable size (460,078 ± 65,780 µm 2 , mean ± SD) from both groups of patients. After microscopic control of tissue preservation and demonstration of RNA integrity, liver biopsy sections were used for LCM (Fig. 3A ).
Quantitative differences in specific CXCL13 mRNA expression in the liver of MC patients were defined and compared with CXCL13 quantity normalized with ß-actin levels in portal tracts (Fig. 3B ). MC patients with active vasculitis were shown to express 4 to 15-fold more CXCL13 than MC patients with non-active vasculitis and 5 to 30-fold more than patients without MC. B cells and on a subset of memory CD4 T cells in healthy people (13, 14) .
Therapy-induced modifications of serum CXCL13 levels
In the present study, serum CXCL13 levels were found to be elevated in by mature B and T cells (32) . A more frequent formation of intraportal lymphoid follicles in MC patients compared to patients without MC has been reported (33) . It is assumed that these structures contribute to antigen presentation in situ, to clonal expansion of antigen-specific B and T cells, and to switching of an acute inflammation into a chronic one (34) .
In this study, CXCL13 expression was recognized in the liver of MC patients with morphological pictures of follicle-like structures, suggesting its major role in the organization and maintenance of ectopic lymphoid tissue. CXCL13 chemokine may attract B cells and initiate the formation of germinal centers, thus contributing to the development of chronic inflammation (35, 36) .
A genetic polymorphism of CXCL13 could explain the different levels of CXCL13 in MC patients compared to those without MC. Although there are no data describing such polymorphism, several high-producer alleles of proinflammatory cytokines have been associated with HCV infection (37, 38) . Whether a CXCL13
high-producer allele is associated with MC patients, remains to be explored. Another possibility is that T-regulatory CD4 + CD25 + cells that are defective in MC patients (39) could influence the production of chemokine by stromal cells. This hypothesis also deserves further investigation.
Of note, no direct correlation between CXCL13 serum levels and circulating viral load was noticed. Though these findings may indicate the lack of a direct effect of the virus on the sources of CXCL13 production, they do not highlight the in situ relation between HCV and CXCL13 producer cells.
HCV minus strand RNA, the viral replicative intermediary, was frequently found in lymph nodes of HCV-infected patients (40) . 
